β-elemene enhances anticancer and anti-metastatic effects of osteosarcoma of ligustrazine in vitro and in vivo

  • Authors:
    • Min Fang
    • Xiaolong Mei
    • Hui Yao
    • Tao Zhang
    • Na Lu
    • Yanshi Liu
    • Wenyue Xu
    • Chunyou Wan
  • View Affiliations

  • Published online on: January 12, 2018     https://doi.org/10.3892/ol.2018.7788
  • Pages: 3957-3964
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The present study aimed to determine the anticancer effects of the combination of β‑elemene and ligustrazine in vitro as well as in in vivo. Following evaluation using an MTT assay, β‑elemene, ligustrazine and the β‑elemene‑ligustrazine combination treatments all exhibited the capacity to inhibit the growth of OS‑732 cells, with inhibitory rates of 43.3, 54.4, and 75.0%, respectively. Using a flow cytometry assay, it was determined that the β‑elemene‑ligustrazine combination possessed the highest apoptotic rate (30.6%). Furthermore, β‑elemene‑ligustrazine combination treatment resulted in the highest downregulation of G protein‑coupled receptor 124, vascular endothelial growth factor, matrix metallopeptidase (MMP)‑2 and MMP‑9 mRNA, and protein expression levels. In addition, the combined treatment led to an increase in the mRNA and protein expression of endostatin, TIMP metallopeptidase inhibitor (TIMP)‑1 and TIMP‑2 in OS‑732 cells. Additionally, β‑elemene‑ligustrazine caused a decrease in nuclear factor‑κB, interleukin‑8, C‑X‑C motif chemokine receptor 4 and urokinase‑type plasminogen activator mRNA expression, as well as an increase in caspase‑3, caspase‑8, and caspase‑9 mRNA expression. In vivo, the β‑elemene‑ligustrazine combination was able to reduce the weight and the bulk of the tumor in BALB/c‑nu/nu nude mice compared with any other group. All the results described above regarding changes to mRNA and protein expression were further confirmed in vivo in the tumor tissue of mice. The results of the present study have suggested that the combination of β‑elemene‑ligustrazine exhibits greater anticancer effects compared with β‑elemene‑ or ligustrazine‑alone treatment.
View Figures
View References

Related Articles

Journal Cover

March-2018
Volume 15 Issue 3

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Fang M, Mei X, Yao H, Zhang T, Lu N, Liu Y, Xu W and Wan C: β-elemene enhances anticancer and anti-metastatic effects of osteosarcoma of ligustrazine in vitro and in vivo. Oncol Lett 15: 3957-3964, 2018
APA
Fang, M., Mei, X., Yao, H., Zhang, T., Lu, N., Liu, Y. ... Wan, C. (2018). β-elemene enhances anticancer and anti-metastatic effects of osteosarcoma of ligustrazine in vitro and in vivo. Oncology Letters, 15, 3957-3964. https://doi.org/10.3892/ol.2018.7788
MLA
Fang, M., Mei, X., Yao, H., Zhang, T., Lu, N., Liu, Y., Xu, W., Wan, C."β-elemene enhances anticancer and anti-metastatic effects of osteosarcoma of ligustrazine in vitro and in vivo". Oncology Letters 15.3 (2018): 3957-3964.
Chicago
Fang, M., Mei, X., Yao, H., Zhang, T., Lu, N., Liu, Y., Xu, W., Wan, C."β-elemene enhances anticancer and anti-metastatic effects of osteosarcoma of ligustrazine in vitro and in vivo". Oncology Letters 15, no. 3 (2018): 3957-3964. https://doi.org/10.3892/ol.2018.7788